Compare SEMR & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SEMR | NVAX |
|---|---|---|
| Founded | 2008 | 1987 |
| Country | United States | United States |
| Employees | 1567 | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.6B |
| IPO Year | 2021 | 1996 |
| Metric | SEMR | NVAX |
|---|---|---|
| Price | $11.94 | $8.49 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 5 | 9 |
| Target Price | $10.00 | ★ $11.33 |
| AVG Volume (30 Days) | 1.1M | ★ 4.4M |
| Earning Date | 03-02-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 309.76 |
| EPS | N/A | ★ 2.58 |
| Revenue | $443,644,000.00 | ★ $1,123,479,000.00 |
| Revenue This Year | $16.85 | N/A |
| Revenue Next Year | $14.35 | N/A |
| P/E Ratio | ★ N/A | $3.47 |
| Revenue Growth | 17.74 | ★ 64.69 |
| 52 Week Low | $6.56 | $5.01 |
| 52 Week High | $11.95 | $11.85 |
| Indicator | SEMR | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 65.11 | 38.12 |
| Support Level | $11.90 | $8.01 |
| Resistance Level | $11.94 | $9.05 |
| Average True Range (ATR) | 0.01 | 0.54 |
| MACD | -0.00 | -0.23 |
| Stochastic Oscillator | 67.39 | 1.81 |
SEMrush Holdings Inc offers an online visibility management software-as-a-service (SaaS) platform enabling its clients globally to identify and reach the right audience for their content. The platform utilizes data and intelligence at the core, surrounded by AI-powered interconnected hubs to provide customers with key data, helping them understand trends and derive actionable insights to improve their websites and social media pages, and distribute relevant content to their targeted customers across a variety of digital channels. The company generates nearly all of its revenue from subscriptions to its online visibility management SaaS platform under a SaaS model. Geographically, it generates maximum revenue from the United States, followed by the United Kingdom and other regions.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.